Schmid John's Insider Trades & SAST Disclosures
Schmid John's most recent trade in Caleres Inc was a trade of 22,405 Common Stock done at an average price of $15.4 . Disclosure was reported to the exchange on March 16, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Schmid John.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.41 per share. | 16 Mar 2025 | 22,405 | 312,016 (0%) | 0% | 15.4 | 345,261 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.10 per share. | 16 Mar 2025 | 11,655 | 300,361 (0%) | 0% | 16.1 | 187,646 | Common Stock |
| UMB Financial Corp. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 32,468 | 32,468 (0%) | 0% | - | Common Stock | |
| UMB Financial Corp. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,818 | 21,818 (0%) | 0% | - | Common Stock | |
| UMB Financial Corp. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 2,629 | 2,629 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.55 per share. | 13 Jan 2025 | 21,692 | 25,592 (0%) | 0% | 4.6 | 98,699 | Common Stock |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 21,692 | 0 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 20,645 | 0 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.54 per share. | 13 Jan 2025 | 20,645 | 46,237 (0%) | 0% | 8.5 | 176,308 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.37 per share. | 13 Jan 2025 | 14,350 | 334,421 (0%) | 0% | 20.4 | 292,310 | Common Stock |
| Poseida Therapeutics Inc | John Schmid | Director | 08 Jan 2025 | 58,950 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 32,076 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 28,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 25,833 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 16,038 | 0 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Sale of securities on an exchange or to another person at price $ 68.32 per share. | 11 Nov 2024 | 22,500 | 60,541 (0%) | 0% | 68.3 | 1,537,200 | Common Stock |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2024 | 3,500 | 57,041 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 12 Aug 2024 | 4,515 | 25,200 (0%) | 0% | 2.2 | 10,147 | Common Stock |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 2.36 per share. | 09 Aug 2024 | 4,285 | 20,685 (0%) | 0% | 2.4 | 10,134 | Common Stock |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,534 | 83,041 (0%) | 0% | 0 | Common Stock | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,534 | 0 | - | - | 2023 Restricted Stock Units | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 19,650 | 58,950 | - | 0 | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 50,000 | 113,159 (0%) | 0% | 0 | Common Stock | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,992 | 1,992 | - | - | 2024 Time-Based Restricted Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 1.91 per share. | 10 May 2024 | 5,400 | 16,400 (0%) | 0% | 1.9 | 10,314 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 37.62 per share. | 06 May 2024 | 12,666 | 348,771 (0%) | 0% | 37.6 | 476,556 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 37.63 per share. | 06 May 2024 | 12,666 | 361,437 (0%) | 0% | 37.6 | 476,613 | Common Stock |
| Design Therapeutics Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 3.74 per share. | 22 Mar 2024 | 17,809 | 26,965 | - | 3.7 | 66,606 | Common Stock |
| Design Therapeutics Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 22 Mar 2024 | 9,156 | 9,156 | - | 3.6 | 33,133 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 54,812 | 374,103 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.65 per share. | 17 Mar 2024 | 11,706 | 323,957 (0%) | 0% | 38.7 | 452,437 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.86 per share. | 17 Mar 2024 | 4,666 | 319,291 (0%) | 0% | 38.9 | 181,321 | Common Stock |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 2.16 per share. | 14 Mar 2024 | 4,500 | 11,000 (0%) | 0% | 2.2 | 9,720 | Common Stock |
| Caleres Inc | W. Schmidt John | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 33.29 per share. | 08 Feb 2024 | 12,668 | 360,995 (0%) | 0% | 33.3 | 421,724 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 30.16 per share. | 11 Jan 2024 | 12,668 | 373,663 (0%) | 0% | 30.2 | 382,120 | Common Stock |
| AnaptysBio Inc | Schmid John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Caleres Inc | W. Schmidt John | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.50 per share. | 02 Dec 2023 | 17,265 | 386,331 (0%) | 0% | 30.5 | 526,583 | Common Stock |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 1,396 | 80,507 (0%) | 0% | 0 | Common Stock | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2023 | 1,396 | 0 | - | - | 2022 Director Restricted Stock Units | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 19,650 | 39,300 | - | 0 | Common Stock | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 2,534 | 2,534 | - | - | 2023 Director Restricted Stock Units | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 42,500 | 63,159 (0%) | 0% | 0 | Common Stock | |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2023 | 86,506 | 408,269 (1%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.12 per share. | 16 Mar 2023 | 5,711 | 321,763 (0%) | 0% | 23.1 | 132,038 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.51 per share. | 16 Mar 2023 | 4,673 | 403,596 (0%) | 0% | 22.5 | 105,189 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Mar 2023 | 77,984 | 362,019 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 25.25 per share. | 09 Mar 2023 | 34,545 | 327,474 (0%) | 0% | 25.2 | 872,261 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2023 | 55,344 | 284,035 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.21 per share. | 02 Dec 2022 | 18,387 | 228,691 (0%) | 0% | 22.2 | 408,375 | Common Stock |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 28,500 | 28,500 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 19,650 | 19,650 | - | 0 | Common Stock | |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 1,396 | 0 | - | - | 2022 Director Restricted Stock Units | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 15,000 | 20,659 (0%) | 0% | 0 | Common Stock | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 44.25 per share. | 05 Jun 2022 | 1,350 | 79,111 (0%) | 0% | 44.3 | 59,738 | Common Stock |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2022 | 1,350 | 1,350 | - | - | 2021 Director Restricted Stock Units | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.03 per share. | 25 Mar 2022 | 5,530 | 247,078 (0%) | 0% | 20.0 | 110,766 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 45,000 | 252,608 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.16 per share. | 16 Mar 2022 | 6,083 | 207,608 (0%) | 0% | 21.2 | 128,716 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2022 | 8,500 | 218,214 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.97 per share. | 11 Mar 2022 | 4,523 | 213,691 (0%) | 0% | 20.0 | 90,324 | Common Stock |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 25,220 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 25,220 | 25,220 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 11,228 | 0 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2021 | 5,659 | 5,659 (0%) | 0% | - | Common Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Oct 2021 | 5,659 | 0 (0%) | 0% | - | Common Stock | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jul 2021 | 25,833 | 25,833 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,228 | 11,228 | - | - | Stock Option (Right to Buy) | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 50.35 per share. | 05 Jun 2021 | 2,116 | 104,061 (0%) | 0% | 50.4 | 106,541 | Common Stock |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2021 | 2,116 | 2,116 | - | - | 2020 Director Restricted Stock Units | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2021 | 150 | 0 | - | - | 2021 Director Restricted Stock Units | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 1,200 | 0 | - | - | 2021 Director Restricted Stock Units | |
| Heartland Financial USA, Inc. | John K. Schmidt | Director | Sale of securities on an exchange or to another person at price $ 50.80 per share. | 05 May 2021 | 5,000 | 101,945 (0%) | 0% | 50.8 | 254,004 | Common Stock |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.78 per share. | 25 Mar 2021 | 3,822 | 209,714 (0%) | 0% | 18.8 | 71,777 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Mar 2021 | 18,000 | 219,651 (0%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.18 per share. | 18 Mar 2021 | 6,115 | 213,536 (0%) | 0% | 18.2 | 111,171 | Common Stock |
| Caleres Inc | John W. Schmidt | President, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.90 per share. | 15 Mar 2021 | 2,675 | 201,651 (0%) | 0% | 18.9 | 50,558 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges